Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia

Clinical Trial

Douglas W Losordo et al. Circulation. 2002.

Abstract

Background: This phase 1/2 study investigated the safety of percutaneous catheter-based gene transfer of naked plasmid DNA encoding for vascular endothelial growth factor 2 (phVEGF2) to left ventricular (LV) myocardium in a prospective, randomized, double-blind, placebo-controlled, dose-escalating study of inoperable patients with class III or IV angina.

Methods and results: A steerable deflectable 8F catheter with a 27-gauge needle at its distal tip was advanced percutaneously to the endocardial surface of the LV in 19 patients (age, 61+/-2 years) with chronic myocardial ischemia who were not candidates for conventional revascularization. Patients were randomized in a double-blind fashion to receive 6 injections (total volume, 6.0 mL) of placebo or phVEGF2 in doses of 200 microg (n=9), 800 microg (n=9), or 2000 microg (n=1) guided by LV electromechanical (NOGA) mapping with a gene-to-placebo ratio of 2:1. A total of 114 LV injections were delivered and caused no hemodynamic alterations, sustained ventricular arrhythmias, ECG evidence of infarction, or ventricular perforation. End-point analysis at 12 weeks disclosed a statistically significant improvement in Canadian Cardiovascular Society (CCS) angina class in phVEGF2-treated versus placebo-treated patients (-1.3 versus -0.1, P=0.04). Remaining efficacy end points--including change in exercise duration (91.8 versus 3.9 seconds), functional improvement by > or =2 CCS classes (9 of 12 versus 1 of 6), and Seattle Angina Questionnaire data--all showed strong trends favoring efficacy of phVEGF2 versus placebo treatment.

Conclusions: This phase 1/2, double-blind, randomized trial provides preliminary data that support safety of phVEGF2 catheter-mediated myocardial gene transfer. The statistically significant reduction in anginal class and strong positive trends for remaining end points suggest that a larger phase 2/3 trial is warranted.

PubMed Disclaimer

Cited by

Current stem cell delivery methods for myocardial repair.
Sheng CC, Zhou L, Hao J. Sheng CC, et al. Biomed Res Int. 2013;2013:547902. doi: 10.1155/2013/547902. Epub 2012 Dec 27. Biomed Res Int. 2013. PMID: 23509740 Free PMC article. Review.
The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells.
Albrecht-Schgoer K, Schgoer W, Holfeld J, Theurl M, Wiedemann D, Steger C, Gupta R, Semsroth S, Fischer-Colbrie R, Beer AG, Stanzl U, Huber E, Misener S, Dejaco D, Kishore R, Pachinger O, Grimm M, Bonaros N, Kirchmair R. Albrecht-Schgoer K, et al. Circulation. 2012 Nov 20;126(21):2491-501. doi: 10.1161/CIRCULATIONAHA.111.076950. Epub 2012 Oct 18. Circulation. 2012. PMID: 23081990 Free PMC article.
Proangiogenic Growth Factor Therapy for the Treatment of Refractory Angina: A Meta-analysis.
Weeraman D, Jones DA, Hussain M, Beirne AM, Hadyanto S, Rathod KS, Whiteford JR, Reid AE, Bourantas CV, Ylä-Herttuala S, Baumbach A, Gersh BJ, Henry TD, Mathur A. Weeraman D, et al. J Soc Cardiovasc Angiogr Interv. 2023 Jan 2;2(1):100527. doi: 10.1016/j.jscai.2022.100527. eCollection 2023 Jan-Feb. J Soc Cardiovasc Angiogr Interv. 2023. PMID: 39132540 Free PMC article. Review.
Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy.
Psaltis PJ, Carbone A, Leong DP, Lau DH, Nelson AJ, Kuchel T, Jantzen T, Manavis J, Williams K, Sanders P, Gronthos S, Zannettino AC, Worthley SG. Psaltis PJ, et al. Int J Cardiovasc Imaging. 2011 Jan;27(1):25-37. doi: 10.1007/s10554-010-9657-5. Epub 2010 Jun 29. Int J Cardiovasc Imaging. 2011. PMID: 20585861
Hedgehog signaling is critical for maintenance of the adult coronary vasculature in mice.
Lavine KJ, Kovacs A, Ornitz DM. Lavine KJ, et al. J Clin Invest. 2008 Jul;118(7):2404-14. doi: 10.1172/JCI34561. J Clin Invest. 2008. PMID: 18568073 Free PMC article.

Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia - PubMed (original) (raw)